Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study
IntroductionDonor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor.MethodsWe evaluated the effect of donor parity on transplant outcomes in a large homogeneou...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1339605/full |
| _version_ | 1797201722642268160 |
|---|---|
| author | Mojtaba Azari Mojtaba Azari Maryam Barkhordar Maryam Barkhordar Tanaz Bahri Tanaz Bahri Soroush Rad Soroush Rad Hosein Kamranzadeh Fumani Hosein Kamranzadeh Fumani Seied Asadollah Mousavi Seied Asadollah Mousavi Sahar Tavakoli Shiraji Sahar Tavakoli Shiraji Morteza Azari Morteza Azari Parisa Shafaroudi Parisa Shafaroudi Mohammad Vaezi Mohammad Vaezi |
| author_facet | Mojtaba Azari Mojtaba Azari Maryam Barkhordar Maryam Barkhordar Tanaz Bahri Tanaz Bahri Soroush Rad Soroush Rad Hosein Kamranzadeh Fumani Hosein Kamranzadeh Fumani Seied Asadollah Mousavi Seied Asadollah Mousavi Sahar Tavakoli Shiraji Sahar Tavakoli Shiraji Morteza Azari Morteza Azari Parisa Shafaroudi Parisa Shafaroudi Mohammad Vaezi Mohammad Vaezi |
| author_sort | Mojtaba Azari |
| collection | DOAJ |
| description | IntroductionDonor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor.MethodsWe evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen.ResultsA total of 1103 allo-HSCT recipients were included. 188 (17%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI).DiscussionThis study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection. |
| first_indexed | 2024-03-07T23:24:41Z |
| format | Article |
| id | doaj.art-4c80cf064bce4fc7acf21cbc98c1136f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T07:52:04Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-4c80cf064bce4fc7acf21cbc98c1136f2024-04-18T09:23:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-02-011410.3389/fonc.2024.13396051339605Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center studyMojtaba Azari0Mojtaba Azari1Maryam Barkhordar2Maryam Barkhordar3Tanaz Bahri4Tanaz Bahri5Soroush Rad6Soroush Rad7Hosein Kamranzadeh Fumani8Hosein Kamranzadeh Fumani9Seied Asadollah Mousavi10Seied Asadollah Mousavi11Sahar Tavakoli Shiraji12Sahar Tavakoli Shiraji13Morteza Azari14Morteza Azari15Parisa Shafaroudi16Parisa Shafaroudi17Mohammad Vaezi18Mohammad Vaezi19Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranHematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranHematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranResearch Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, IranHematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, IranIntroductionDonor choosing remains to play a pivotal role in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Numerous criteria beyond HLA compatibility impact the selection of a suitable donor.MethodsWe evaluated the effect of donor parity on transplant outcomes in a large homogeneously treated population that received an HLA-matched allo-HSCT between 2010 and 2021 at our center. All patients were transplanted from a peripheral blood stem cell source following a myeloablative Busulfan-based conditioning and an identical protocol for graftversus-host disease (GVHD) prophylaxis regimen.ResultsA total of 1103 allo-HSCT recipients were included. 188 (17%) had transplants from parous female donors, whereas 621 (56.30%) and 294 (26.70%) received transplants from male and nulliparous female donors, respectively. HSCTs from parous female donors compared to male and nulliparous females were associated with a significantly higher incidence of grade III-IV acute (a) GVHD (55.27% vs. 11.34 and 10.84%) and extensive chronic (c) GVHD (64.32% vs. 15.52 and 13.65%), as well as lower relapse incidence (RI).DiscussionThis study finds that while parous female donors are associated with higher incidences of grade III-IV aGVHD and extensive cGVHD post-allo-HSCT, the advantages, such as a lower RI, outweigh the risks. The results of our study provide valuable insights for donor selection.https://www.frontiersin.org/articles/10.3389/fonc.2024.1339605/fullgraft-versus-host disease (GVHD)hematopoietic stem cell transplantation (HSCT)donor parityoverall survivalrelapse incidence |
| spellingShingle | Mojtaba Azari Mojtaba Azari Maryam Barkhordar Maryam Barkhordar Tanaz Bahri Tanaz Bahri Soroush Rad Soroush Rad Hosein Kamranzadeh Fumani Hosein Kamranzadeh Fumani Seied Asadollah Mousavi Seied Asadollah Mousavi Sahar Tavakoli Shiraji Sahar Tavakoli Shiraji Morteza Azari Morteza Azari Parisa Shafaroudi Parisa Shafaroudi Mohammad Vaezi Mohammad Vaezi Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study Frontiers in Oncology graft-versus-host disease (GVHD) hematopoietic stem cell transplantation (HSCT) donor parity overall survival relapse incidence |
| title | Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study |
| title_full | Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study |
| title_fullStr | Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study |
| title_full_unstemmed | Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study |
| title_short | Determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants: a retrospective, single-center study |
| title_sort | determining the predictive impact of donor parity on the outcomes of human leukocyte antigen matched hematopoietic stem cell transplants a retrospective single center study |
| topic | graft-versus-host disease (GVHD) hematopoietic stem cell transplantation (HSCT) donor parity overall survival relapse incidence |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1339605/full |
| work_keys_str_mv | AT mojtabaazari determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT mojtabaazari determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT maryambarkhordar determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT maryambarkhordar determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT tanazbahri determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT tanazbahri determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT soroushrad determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT soroushrad determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT hoseinkamranzadehfumani determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT hoseinkamranzadehfumani determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT seiedasadollahmousavi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT seiedasadollahmousavi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT sahartavakolishiraji determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT sahartavakolishiraji determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT mortezaazari determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT mortezaazari determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT parisashafaroudi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT parisashafaroudi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT mohammadvaezi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy AT mohammadvaezi determiningthepredictiveimpactofdonorparityontheoutcomesofhumanleukocyteantigenmatchedhematopoieticstemcelltransplantsaretrospectivesinglecenterstudy |